MDxHealth Reports Strong FY25 Revenue Growth, Significant EBITDA Improvement, Reaffirms Robust 2026 Guidance

summarizeSummary

MDxHealth reported strong 20% revenue growth for FY25 and a 92% improvement in Adjusted EBITDA loss, while reaffirming its robust 2026 revenue guidance and a target of 10% Adjusted EBITDA margin by year-end.

check_boxKey Events

• Strong Full-Year 2025 Financial Results

  MDxHealth reported full-year 2025 revenue of $107.9 million, a 20% increase over 2024, and fourth-quarter revenue of $29.5 million, up 19% year-over-year. This follows the preliminary revenue figures reported on 2026-01-12.

• Significant Adjusted EBITDA Improvement

  The company achieved a 92% improvement in Adjusted EBITDA for the full year 2025, reducing the loss to ($1.1) million compared to ($14.7) million in 2024, indicating strong progress towards profitability.

• Robust 2026 Guidance Reaffirmed

  MDxHealth maintained its previously issued 2026 revenue guidance of $137-140 million, representing 27-30% growth, and confirmed its view of driving progress toward a 10% Adjusted EBITDA margin exiting 2026.

• Interim CFO Appointed

  Ron Kalfus has been appointed interim Chief Financial Officer, effective February 26, 2026.

auto_awesomeAnalysis

MDxHealth SA reported strong financial results for the full year 2025, with revenue increasing 20% to $107.9 million. The company also demonstrated significant progress towards profitability, improving its Adjusted EBITDA loss by 92% to ($1.1) million for the full year. This positive momentum is reinforced by the reaffirmation of robust 2026 revenue guidance of $137-140 million, representing 27-30% growth, and a target of a 10% Adjusted EBITDA margin exiting 2026. While cash and cash equivalents decreased to $29.0 million, the improved operational performance and clear path to profitability outlined in the guidance are key positive signals for investors. The appointment of an interim CFO is a secondary development.